Otolith Labs

Otolith Labs is pioneering the first medical wearable for the treatment of chronic vertigo, a symptom experienced by 11.6 million Americans. Otolith’s patented non-invasive technology received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation. Utilizing our cutting-edge science, engineering, and clinical research, we developed a non-invasive Vestibular Resonance Therapy (nVRT) to deliver energy to the vestibular system. We look forward to making this technology available to treat vertigo symptoms and vestibular disorders as we secure our regulatory clearances in the U.S. and beyond.